SELLAS Life Sciences Group, Inc. Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
SELLAS Life Sciences Group, Inc. (SLS) had Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount of $700.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions · last filed 2026-08-11
- 2026-06-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $700.00K.
- 2026-03-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $800.00K.
- 2025-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $1.00M.
- 2025-09-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $1.20M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount |
|---|---|
| 2026-06-30 | $700.00K 10-Q · filed 2026-08-11 |
| 2026-03-31 | $800.00K 10-Q · filed 2026-05-12 |
| 2025-12-31 | $1.00M 10-K · filed 2026-03-19 |
| 2025-09-30 | $1.20M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $1.50M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $1.70M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $1.30M 10-K · filed 2025-03-20 |
| 2024-09-30 | $1.60M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $1.90M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $2.50M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $2.90M 10-K · filed 2024-03-28 |
| 2023-09-30 | $3.40M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $3.80M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $4.30M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $2.90M 10-K · filed 2023-03-16 |
| 2022-09-30 | $3.40M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $3.60M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $4.00M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $2.10M 10-K · filed 2022-03-31 |
| 2021-09-30 | $2.20M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $2.40M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $2.50M 10-Q · filed 2021-05-13 |
| 2020-09-30 | $800.00K 10-Q · filed 2020-11-13 |
| 2020-06-30 | $1.00M 10-Q · filed 2020-08-13 |
| 2020-03-31 | $1.10M 10-Q · filed 2020-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |